Relationship between level of PD-L1 expression and outcomes in the KEYNOTE-010 study of pembrolizumab vs docetaxel for previously treated, PD-L1-Positive NSCLC.

被引：9

作者：

Baas, Paul

Garon, Edward B.

Herbst, Roy S.

Felip, Enriqueta

Perez-Gracia, Jose Luis

Han, Ji-Youn

Molina, Julian R.

Kim, Joo-Hang

Arvis, Catherine Dubos

Ahn, Myung-Ju

Majem, Margarita

Fidler, Mary J.

Barlesi, Fabrice

Castro, Gilberto

Garrido, Marcelo

Shentu, Yue

Lubiniecki, Gregory M.

Im, Ellie

Kim, Dong-Wan

机构：

[1] Netherlands Canc Inst, Amsterdam, Netherlands

[2] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

[3] Yale Univ, Yale Canc Ctr, Sch Med, New Haven, CT USA

[4] Vall dHebron Univ, Barcelona, Spain

[5] Univ Navarra Clin, Pamplona, Spain

[6] Natl Canc Ctr, Goyang, South Korea

[7] Mayo Clin, Rochester, MN USA

[8] CHA Univ, CHA Bundang Med Ctr, Gyeonggi Do, South Korea

[9] Ctr Francois Baclesse, Caen, France

[10] Sungkyunkwan Univ, Div Hematol & Oncol, Dept Med, Samsung Med Ctr,Sch Med, Seoul, South Korea

[11] Hosp Santa Creu & Sant Pau, Barcelona, Spain

[12] Rush Univ, Med Ctr, Chicago, IL 60612 USA

[13] Aix Marseille Univ, AP HM, Marseille, France

[14] Inst Canc Estado Sao Paulo, Sao Paulo, Brazil

[15] Pontificia Univ Catolica Chile, Santiago, Chile

[16] Merck & Co Inc, Kenilworth, NJ USA

[17] Seoul Natl Univ Hosp, Seoul, South Korea

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.9015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9015

引用

页数：3